TLT2抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using TLT2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HEK293 cells using TLT2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using TLT2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using TLT2 mouse mAb with DAB staining.    

  
  

The TLT2 (TREM-like transcript 2) antibody is a research tool targeting the TLT2 protein, a member of the TREM (Triggering Receptor Expressed on Myeloid cells) family. TLT2 is primarily expressed on myeloid cells, including macrophages, monocytes, and dendritic cells, and plays a role in modulating immune responses. It interacts with ligands such as PGLYRP1 (peptidoglycan recognition protein 1) to regulate inflammatory pathways, though its signaling mechanisms remain less defined compared to other TREM family members. TLT2 is implicated in both innate and adaptive immunity, influencing processes like cytokine secretion, phagocytosis, and T-cell activation.

Antibodies against TLT2 are used to study its expression, localization, and function in immune regulation. They enable detection via techniques like flow cytometry, immunohistochemistry, and Western blot, aiding in explorations of TLT2’s role in diseases such as sepsis, autoimmune disorders, and cancer. Recent studies suggest TLT2 may act as a checkpoint regulator, with potential therapeutic applications in modulating immune overactivation or tolerance. However, its dual role in pro- and anti-inflammatory responses complicates mechanistic understanding.

TLT2 antibodies also help dissect its structural features, including extracellular immunoglobulin-like domains and signaling motifs. Ongoing research aims to clarify ligand interactions and downstream pathways, positioning TLT2 as a promising target for immunotherapy. Despite progress, further validation in disease models and human trials is needed to harness its full therapeutic potential.